首页> 外文期刊>Heart and Lung: The Journal of Critical Care >The efficacy of noninvasive ventilation in managing postextubation respiratory failure: A meta-analysis
【24h】

The efficacy of noninvasive ventilation in managing postextubation respiratory failure: A meta-analysis

机译:无创通气的疗效管理postextubation呼吸衰竭:A荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: To determine the effectiveness of noninvasive ventilation (NIV) in the management of postextubation respiratory failure. Methods: Databases including PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were searched to find relevant trials. Randomized and quasi-randomized trials studying NIV in adult patients with postextubation respiratory failure were included. Effects on primary outcomes (i.e., reintubation rate, and ICU or/and hospital mortality) were accessed in this meta-analysis. Results: Ten trials involving 1382 patients were included: two used NIV in patients with established postextubation respiratory failure, and eight used NIV immediately after extubation. The use of NIV following extubation for patients (n=302) with established respiratory failure did not decrease the reintubation rate (relative risk [RR] 1.02, 95% confidence interval [CI] 0.83-1.25) and ICU mortality (RR 1.14, 95% CI 0.43-3.00), compared to standard medical therapy (SMT). Early application of NIV after extubation (n=1080) also did not decrease the reintubation rate (RR 0.75, 95% CI 0.45-1.15) significantly. However, in the planned extubation subgroup (n=849), there were significant reductions in the reintubation rate (RR 0.65, 95% CI 0.46-0.93), ICU mortality rate (RR 0.41, 95% CI 0.21-0.82), and hospital mortality rate (RR 0.59, 95% CI 0.38-0.93) compared to SMT. Conclusion: Current evidence suggests that the use of NIV in patients with established postextubation respiratory failure should be monitored cautiously. Early use of NIV can benefit patients with planned extubation by decreasing the reintubation rate and the ICU and hospital mortality rates.
机译:作品简介:以确定的有效性无创通气(NIV)管理postextubation呼吸衰竭。数据库包括PubMed、EMBASE,科克伦中心注册的对照试验搜索找到相关试验。和quasi-randomized试验在成人学习和合postextubation呼吸衰竭患者被包括在内。再插管率、加护病房或/和医院在这个荟萃分析死亡率)访问。结果:10个试验包括1382名患者包括:两个和合患者使用建立postextubation呼吸衰竭,和八个和合拔管后立即使用。和合病人拔管后的使用与建立呼吸衰竭(n = 302)不是再插管率(相对风险降低(RR) 1.02, 95%可信区间[CI]0.83 - -1.25)和ICU死亡率(相对危险度1.14,95%可信区间0.43 - -3.00),而标准药物治疗(SMT)。(n = 1080)也没有降低再插管率(相对危险度0.75,95%可信区间0.45 - -1.15)。然而,在拔管组计划(n = 849),有显著的减少再插管率(相对危险度0.65,95%可信区间0.46 - -0.93),ICU死亡率(相对危险度0.41,95%可信区间0.21 - -0.82),和医院的死亡率(相对危险度0.59,95%可信区间0.38 - -0.93)相比,SMT。有证据表明,使用和合的病人与现有postextubation呼吸失败应该谨慎地监控。和合患者可以受益计划拔管通过减少再插管率和ICU医院死亡率。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号